Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment

Ann Palliat Med. 2020 Mar;9(2):512-516. doi: 10.21037/apm.2020.01.09. Epub 2020 Mar 18.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Ado-Trastuzumab Emtansine / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / mortality
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Erb-b2 Receptor Tyrosine Kinases / metabolism*
  • Female
  • Humans
  • Randomized Controlled Trials as Topic

Substances

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal, Humanized
  • Erb-b2 Receptor Tyrosine Kinases
  • ERBB2 protein, human